Current Report Filing (8-k)
July 06 2021 - 6:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 30, 2021
PHARMACYTE BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
Nevada
|
333-68008
|
62-1772151
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
23046 Avenida de la Carlota, Suite 600
Laguna Hills, CA
|
92653
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
|
Registrant's telephone number, including area code:
(917) 595-2850
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
|
|
|
|
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [_]
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Item 5.07 Submission of Matters to a Vote of
Security Holders.
The 2021 Annual Meeting of
Stockholders (“Annual Meeting”) of PharmaCyte Biotech, Inc. (“Company”) was held on June 16, 2021 and adjourned
until concluded on June 30, 2021. The following proposals were approved at the Annual Meeting by the votes indicated:
Proposal One: To elect
seven directors as nominated by the Board of Directors, each to serve a one-year term.
Name
|
Total Votes
for Director
|
Total Votes
Withheld from
Director
|
Total Broker
Non-Votes
|
Kenneth L. Waggoner, JD
|
647,529,293
|
55,195,927
|
701,253,249
|
Gerald W. Crabtree, PhD
|
657,017,969
|
45,707,251
|
701,253,249
|
Thomas Liquard
|
649,342,060
|
53,383,160
|
701,253,249
|
Thomas C.K. Yuen
|
654,682,670
|
48,042,550
|
701,253,249
|
Michael M. Abecassis, MD
|
654,699,429
|
48,025,791
|
701,253,249
|
Raymond C.F. Tong, MD
|
654,764,465
|
48,960,755
|
701,253,249
|
Carlos A. Trujillo, CPA
|
650,408,779
|
52,316,441
|
701,253,249
|
Proposal Two: To approve
a Certificate of Amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of common stock
of the Company.
|
Total Votes
|
For
|
1,262,698,401
|
Against
|
204,989,730
|
Abstain
|
9,776,868
|
Broker Non-Votes
|
0
|
Proposal Three: To approve
the 2021 Equity Incentive Plan.
|
Total Votes
|
For
|
565,718,942
|
Against
|
116,366,297
|
Abstain
|
20,639,981
|
Broker Non-Votes
|
701,253,249
|
Proposal Four: To ratify
the appointment of Armanino LLP as the Company’s independent registered public accounting firm for the fiscal year ending April
30, 2022.
|
Total Votes
|
For
|
1,355,187,754
|
Against
|
31,987,304
|
Abstain
|
16,803,411
|
Broker Non-Votes
|
0
|
Item 8.01 Other Events.
On July 2, 2021, pursuant
to stockholder approval at the Annual Meeting of Stockholders, the Company filed with the Secretary of State of the State of Nevada a
Certificate of Amendment (“Certificate of Amendment”) to its Articles of Incorporation, as amended, to increase the number
of authorized shares to Fifty Billion Ten Million (50,010,000,000) shares, of which Fifty Billion (50,000,000,000) shares, with a par
value of $0.0001 per share, are designated “Common Stock” and of which Ten Million (10,000,000) shares, with a par value of
$0.0001 per share, are designated “Preferred Stock.”
The Certificate of Amendment
is filed as Exhibit 99.1, and is incorporated herein by reference.
Attached as Exhibit 99.2 is
an amendment to the Company’s by-laws, which is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: July 2, 2021
|
PHARMACYTE BIOTECH, INC.
|
|
|
|
By:
|
/s/ Kenneth L. Waggoner
|
|
|
Kenneth L. Waggoner
Chief Executive Officer, President and General Counsel
|